Literature DB >> 18176973

Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B.

Xiao-Ling Wang1, Song-Gang Xie, Ling Zhang, Wei-Xia Yang, Xing Wang, Hong-Zhi Jin.   

Abstract

AIM: To compare the ligase detection reaction (LDR) and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B infection.
METHODS: Mixtures of plasmids and serum samples from 52 chronic hepatitis B patients with low abundant lamivudine-resistant mutations were tested with LDR and real-time PCR. Time required and reagent cost for both assays were evaluated.
RESULTS: Real-time PCR detected 100, 50, 10, 1 and 0.1% of YIDD plasmid, whereas LDR detected 100, 50, 10, 1, 0.1, and 0.01% of YIDD plasmid, in mixtures with YMDD plasmid of 10(6) copies/mL. Among the 52 clinical serum samples, completely concordant results were obtained for all samples by both assays, and 39 YIDD, 9 YVDD, and 4 YIDD/YVDD were detected. Cost and time required for LDR and real-time PCR are 60/80 CNY (8/10.7 US dollars) and 4.5/2.5 h, respectively.
CONCLUSION: LDR and real-time PCR are both sensitive and inexpensive methods for monitoring low abundant YMDD mutants during lamivudine therapy in patients with chronic hepatitis B. LDR is more sensitive and less expensive, while real-time PCR is more rapid.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18176973      PMCID: PMC2673375          DOI: 10.3748/wjg.14.120

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.

Authors:  Man-Fung Yuen; Takanobu Kato; Masashi Mizokami; Annie On-On Chan; John Chi-Hang Yuen; He-Jun Yuan; Danny Ka-Ho Wong; Siu-Man Sum; Irene Oi-Lin Ng; Sheung-Tat Fan; Ching-Lung Lai
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

2.  Dynamics of hepatitis B virus resistance to lamivudine.

Authors:  Coralie Pallier; Laurent Castéra; Alexandre Soulier; Christophe Hézode; Patrice Nordmann; Daniel Dhumeaux; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 3.  A review of entecavir in the treatment of chronic hepatitis B infection.

Authors:  Anastasia Rivkin
Journal:  Curr Med Res Opin       Date:  2005-11       Impact factor: 2.580

4.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.

Authors:  Y F Liaw; R N Chien; C T Yeh; S L Tsai; C M Chu
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

5.  YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.

Authors:  Zhong-Min Huang; Qi-Wen Huang; Ya-Qin Qin; Yan-Zhuan He; Hou-Ji Qin; Yiao-Nan Zhou; Xiang Xu; Mei-Jin Huang
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

6.  Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment.

Authors:  Toshihiko Kirishima; Takeshi Okanoue; Yukiko Daimon; Yoshito Itoh; Hideki Nakamura; Atsuhiro Morita; Tetsuya Toyama; Masahito Minami
Journal:  J Hepatol       Date:  2002-08       Impact factor: 25.083

7.  The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation.

Authors:  Suzan D Pas; Robert A de Man; Edwin Fries; Albert D M E Osterhaus; Hubert G M Niesters
Journal:  J Clin Virol       Date:  2002-07       Impact factor: 3.168

8.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

Authors:  M I Allen; M Deslauriers; C W Andrews; G A Tipples; K A Walters; D L Tyrrell; N Brown; L D Condreay
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

9.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

10.  Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.

Authors:  Man-Fung Yuen; He-Jun Yuan; Erwin Sablon; Danny Ka-Ho Wong; Annie On-On Chan; Benjamin Chun-Yu Wong; Ching-Lung Lai
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

View more
  1 in total

1.  Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.

Authors:  Hui Zhang; Jianchun Xian; Yang Li; Li Xiao; Lu Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-30       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.